BuybackJun 11, 2026, 08:32 AM
Propanc Biopharma Approves $5.0M Share Repurchase Program
AI Summary
Propanc Biopharma, Inc. has approved a share repurchase program, authorizing the company to buy back up to $5.0 million of its common stock. This decision reflects management's belief that the company is significantly undervalued, especially given recent advancements of its lead asset, PRP, towards a pivotal Phase 1b clinical study for metastatic cancer. The company also highlighted its US FDA Orphan Drug Designation for pancreatic cancer, providing seven-year market exclusivity post-approval, and strategic partnerships. The program aims to enhance shareholder value and signals management's confidence in the company's long-term prospects.
Key Highlights
- Propanc Biopharma approved a share repurchase program for up to $5.0 million of common stock.
- The company's lead asset, PRP, is advancing towards a pivotal Phase 1b First-In-Human study.
- The Phase 1b study will involve 30 to 40 advanced cancer patients.
- US FDA Orphan Drug Designation for pancreatic cancer provides 7-year market exclusivity post-approval.
- Repurchases will be made when the market price is believed to understate intrinsic value.
Price Impact
More from PPCB